{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T10:45:53Z","timestamp":1773312353228,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajogmfm.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics & Gynecology MFM"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.ajogmf.2019.100051","type":"journal-article","created":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T12:57:21Z","timestamp":1569848241000},"page":"100051","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacokinetics of 17 alpha hydroxyprogesterone caproate in singleton pregnancy and its influence of maternal body size measures"],"prefix":"10.1016","volume":"1","author":[{"given":"Micaela","family":"Della Torre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3147-4551","authenticated-orcid":false,"given":"Christopher","family":"Enakpene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samath","family":"Ravangard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"DiGiovanni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Deyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Whelan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monique","family":"Sutherland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5570-7562","authenticated-orcid":false,"given":"James","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajogmf.2019.100051_bib2","article-title":"Birth: final data for 2016","author":"Martin","year":"2018","journal-title":"National Vital Statistics Reports 67"},{"key":"10.1016\/j.ajogmf.2019.100051_bib3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ajog.2011.03.048","article-title":"Progesterone receptor polymorphisms and clinical response to 17-alpha-hydroxyprogesterone caproate","volume":"205","author":"Manuck","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2019.100051_bib4","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa035140","article-title":"Prevention of recurrent preterm delivery by 17 alphahydroxy- progesterone caproate","volume":"348","author":"Meis","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajogmf.2019.100051_bib5","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.ajog.2015.08.014","article-title":"Does 17-alpha hydroxyprogesterone caproate prevent recurrent preterm birth in obese women?","volume":"213","author":"Heyborne","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2019.100051_bib6","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ajog.2012.08.015","article-title":"Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation","volume":"207","author":"Caritis","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2019.100051_bib7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.reprotox.2011.10.017","article-title":"17alpha Hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth","volume":"33","author":"Merlob","year":"2012","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.ajogmf.2019.100051_bib8","doi-asserted-by":"crossref","first-page":"B11","DOI":"10.1016\/j.ajog.2017.01.022","article-title":"The choice of progestogen for theprevention of preterm birth in women with singleton pregnancy and prior pretermbirth","volume":"216","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2019.100051_bib9","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1053\/j.semperi.2014.08.013","article-title":"Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations","volume":"38","author":"Feghali","year":"2014","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.ajogmf.2019.100051_bib10","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ajog.2013.10.008","article-title":"Relationship between 17-alpha hydroxyprogesterone caproateconcentration and spontaneous preterm birth","volume":"210","author":"Caritis","year":"2014","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2019.100051_bib11","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/bcp.12990","article-title":"Population pharmacokinetics of 17\u03b1-hydroxyprogesterone caproate in singleton gestation","volume":"82","author":"Sharma","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ajogmf.2019.100051_bib12","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1055\/s-0037-1617453","article-title":"Impact of obesity on the rate of recurrent spontaneous pretermbirth in women treated with 17-alpha hydroxyprogesterone caproate","volume":"35","author":"Hauspurg","year":"2018","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.ajogmf.2019.100051_bib13","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/BF01070904","article-title":"Optimal sampling times for pharmacokinetic experiments","volume":"9","author":"D'Argenio","year":"1981","journal-title":"J\u00a0Pharmacokinet Biopharm"},{"key":"10.1016\/j.ajogmf.2019.100051_bib14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40262-013-0123-0","article-title":"Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy","volume":"53","author":"Fischer","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ajogmf.2019.100051_bib15","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ajog.2010.06.029","article-title":"Betamethasone in pregnancy:influence of maternal body weight and multiple gestation on pharmacokinetics","volume":"203","author":"Della Torre","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2019.100051_bib16","first-page":"1174","article-title":"Simultaneous quantitation of 17alpha-hydroxyprogesterone caproate,17alpha-hydroxyprogesterone and progesterone in human plasma using high performanceliquid chromatography-mass spectrometry (HPLC-MS\/MS)","volume":"48","author":"Zhang","year":"2008","journal-title":"J\u00a0PharmBiomed Anal"},{"key":"10.1016\/j.ajogmf.2019.100051_bib17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10928-011-9228-y","article-title":"Comparison of Nonmem 7.2 estimation methods and parallel processing efficiency on a target-mediated drug disposition model","volume":"39","author":"Gibiansky","year":"2012","journal-title":"J\u00a0Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.ajogmf.2019.100051_bib18","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10928-015-9428-y","article-title":"A\u00a0pharmacometric case study regarding the sensitivity of structural model parameter estimation to error in patient reported dosing times","volume":"42","author":"Knights","year":"2015","journal-title":"J\u00a0Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.ajogmf.2019.100051_bib19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-2125.2004.02157.x","article-title":"What is the best size descriptor to use for pharmacokinetic studies in the obese?","volume":"58","author":"Green","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ajogmf.2019.100051_bib20","doi-asserted-by":"crossref","first-page":"i16","DOI":"10.1093\/bja\/aeq312","article-title":"Dose adjustment of anaesthetics in the morbidly obese","volume":"105","author":"Ingrande","year":"2010","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.ajogmf.2019.100051_bib21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.phrs.2018.02.012","article-title":"Lean body weight is the best scale for venous thromboprophylaxis algorithm in severely obese patients undergoing bariatric surgery","volume":"131","author":"Gaborit","year":"2018","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ajogmf.2019.100051_bib22","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","article-title":"Quantification of lean bodyweight","volume":"44","author":"Janmahasatian","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ajogmf.2019.100051_bib23","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/archinte.1916.00080130010002","article-title":"Clinical calorimetry. Tenth Paper. A formula to estimate the approximate surface area if height and weight be known","volume":"17","author":"DuBois","year":"1916","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ajogmf.2019.100051_bib24","first-page":"303","article-title":"A\u00a0formula to estimate the approximate surface area if height and weight be known. 1916","volume":"5","author":"Du Bois","year":"1989","journal-title":"Nutrition"},{"key":"10.1016\/j.ajogmf.2019.100051_bib25","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0021-9681(72)90027-6","article-title":"Indices of relative weight and obesity","volume":"25","author":"Keys","year":"1972","journal-title":"J\u00a0Chronic Dis"},{"key":"10.1016\/j.ajogmf.2019.100051_bib26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0169-2607(98)00098-4","article-title":"A\u00a0procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models","volume":"59","author":"Parke","year":"1999","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.ajogmf.2019.100051_bib27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1011555016423","article-title":"Evaluating pharmacokinetic\/pharmacodynamics models using the posterior predictive check","volume":"28","author":"Yano","year":"2001","journal-title":"J\u00a0Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.ajogmf.2019.100051_bib28","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/obr.12440","article-title":"From the BMI paradox to the obesity paradox: the obesity\u2013mortality association in coronary heart disease","volume":"17","author":"Antonopoulos","year":"2016","journal-title":"Obes Rev"},{"key":"10.1016\/j.ajogmf.2019.100051_bib29","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1126\/science.276.5309.122","article-title":"A\u00a0general model for the origin of allometric scaling laws in biology","volume":"276","author":"West","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.ajogmf.2019.100051_bib30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ajog.2011.03.028","article-title":"Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation","volume":"205","author":"Caritis","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2019.100051_bib31","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1124\/dmd.108.021444","article-title":"Identification of enzymes involved in the metabolism of 17alphahydroxyprogesterone caproate: an effective agent for prevention of preterm birth","volume":"36","author":"Sharma","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ajogmf.2019.100051_bib32","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ajog.2004.08.030","article-title":"Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy","volume":"192","author":"Tracy","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2019.100051_bib33","first-page":"963","article-title":"ACOG Committee Opinion number 419 October 2008 (replaces no. 291, November 2003). Use of progesterone to reduce preterm birth","volume":"112","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2019.100051_bib34","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ajog.2015.04.018","article-title":"Relation of body mass index to frequency of recurrent preterm birth in women treated with 17-alphahydroxyprogesterone caproate","volume":"213","author":"Co","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2019.100051_bib35","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3109\/14767058.2013.765847","article-title":"Rates of recurrent preterm birth by maternal body habitus in women receiving 17alpha-hydroxyprogesterone caproate","volume":"26","author":"Timofeev","year":"2013","journal-title":"J\u00a0Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ajogmf.2019.100051_bib36","first-page":"667","article-title":"The impact of maternal body mass on the effectiveness of 17 alphahydroxyprogesterone caproate","volume":"53","author":"Ventolini","year":"2008","journal-title":"J\u00a0Reprod Med"},{"key":"10.1016\/j.ajogmf.2019.100051_bib37","first-page":"161S","article-title":"The effectiveness of 17 alpha hydroxyprogesterone caproate in obese women for the prevention of preterm delivery","volume":"123","author":"Ngai","year":"2014","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajogmf.2019.100051_bib38","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ajog.2012.03.010","article-title":"Progesterone and preterm birth prevention: translating clinical trials data into clinical practice","volume":"206","year":"2012","journal-title":"Am J Obstet Gynecol"}],"container-title":["American Journal of Obstetrics & Gynecology MFM"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589933319300849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589933319300849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T23:45:22Z","timestamp":1762904722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589933319300849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S2589933319300849"],"URL":"https:\/\/doi.org\/10.1016\/j.ajogmf.2019.100051","relation":{},"ISSN":["2589-9333"],"issn-type":[{"value":"2589-9333","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics of 17 alpha hydroxyprogesterone caproate in singleton pregnancy and its influence of maternal body size measures","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics & Gynecology MFM","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajogmf.2019.100051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100051"}}